| Literature DB >> 31998403 |
Peng Wu1,2,3, Zhengquan Huang1,2, Jinjun Shan4,5, Zichen Luo4,5, Nongshan Zhang1,2, Songjiang Yin1,2, Cunsi Shen4,5, Runlin Xing1,2, Wei Mei1,2, Yancheng Xiao1,2, Bo Xu1,2, Jun Mao1,2, Peimin Wang1,2.
Abstract
BACKGROUND: Our previous clinical evidence suggested that the direct application of "Sanse powder" the main ingredient of "Yiceng" might represent an alternative treatment for knee osteoarthritis. However, the mechanism underlying its effect is poorly understood. In this study, we investigated the mechanism of the effect of direct "Sanse powder" application for the treatment of knee osteoarthritis (KOA) in rats by using lipidomics.Entities:
Keywords: Direct application “Sanse powder” therapy; KOA lipidomics; LC–MS; Prescription
Year: 2020 PMID: 31998403 PMCID: PMC6979340 DOI: 10.1186/s13020-020-0290-5
Source DB: PubMed Journal: Chin Med ISSN: 1749-8546 Impact factor: 5.455
Fig. 1“Sanse powder” can alleviate the symptoms of KOA. Notes. a Cartilage histomorphology of each group stained with H&E, 40×, scale bar = 100 μm. b Representative synovial tissues of each group stained with H&E, 400×, scale bar = 50 um. c, d MWT and cold pain threshold of each group. #P < 0.05, ##P < 0.01 vs. control group; *P < 0.05, **P < 0.01 vs KOA group (n = 7). e, f Representative protein bands for each group. #P < 0.05, ##P < 0.01 vs. control group; *P < 0.05, **P < 0.01 vs. KOA group. g Representative gene bands for each group. #P < 0.05, ##P < 0.01 vs. control group; *P < 0.05, **P < 0.01 vs. KOA group. h Levels of TNF-α and IL-1β in rat serum were detected by ELISA. #P < 0.05, ##P < 0.01 vs. control group; *P < 0.05, **P < 0.01 vs. KOA group
Fig. 2Total ion chromatogram (TIC) of the methanol extract acquired by LTQ-Orbitrap MS in the positive (a) and negative (b) ion modes
The chemical components identified in the “Sanse powder” water extract
| (A) positive ion mode | |||||
|---|---|---|---|---|---|
| No. | Components | Chemical formula | ESI+, m/z | RT (min) | References |
| 1 | Arginine | C6H14N4O2 | 175.11895 [M+H]+, 116.70, 175.19, 71.84 | 0.63 | [ |
| 2 | Gentiopicroside | C16H20O9 | 357.11800 | 3.20 | * |
| 3 | Ferulic acid | C10H10O4 | 195.06519 [M+H]+, 176.91, 137.88, 120.88 | 3.20 | [ |
| 4 | Strychnine | C21H22N2O2 | 335.1754 [M+H]+, 222.04, 234.09, 264.10 | 3.66 | [ |
| 5 | Brucine | C23H26N2O4 | 395.19653 [M+H]+ 324.11, 367.17, 350.18 | 3.99 | [ |
| 6 | Strychnine N-oxide | C21H22N2O3 | 351.17031 [M+H]+, 334.24, 306.16 | 4.33 | [ |
| 7 | Vomicine | C22H24N2O4 | 381.18088 [M+H]+, 324.14, 264.11, 306.17 | 5.06 | [ |
| 8 | Rutin | C27H30O16 | 611.16066 [M+H]+, 257.24, 285.20 | 6.13 | [ |
| 9 | Forsythoside A | C29H36O15 | 647.19464 [M+Na]+, 347.17, 321.13 | 6.46 | [ |
| 10 | Pinoresinol-β- | C26H32O11 | 543.18368 [M+Na]+, 218.93, 289.13 | 7.10 | [ |
| 11 | Phillyrin | C27H34O11 | 557.19933 [M+Na]+, 291.25, 218.96 | 10.38 | [ |
| 12 | Licorice-saponin G2 | C42H62O17 | 839.40597 [M+H]+, 487.50, 627.38 | 16.92 | [ |
| 13 | Senkyunolides A | C12H16O2 | 193.1223 [M+H]+, 193.11, 174.95, 146.96 | 18.59 | [ |
| 14 | Imperatorin | C16H14O4 | 271.09648 | 21.80 | * |
| 15 | Glycycoumarin | C21H20O6 | 369.13326 [M+H]+, 191.11, 285.09, 148.86 | 21.67 | [ |
| 16 | Curcymin | C21H20O6 | 369.13326 | 21.67 | * |
| 17 | Ligustilide | C12H14O2 | 191.10665 | 21.82 | * |
| 18 | 3-Butylphthalide | C12H14O2 | 191.10665 [M+H]+, 191.07, 144.92, 172.92 | 21.82 | [ |
| 19 | Osthole | C15H16O3 | 245.11722 | 23.17 | * |
| 20 | Cryptotanshinone | C19H20O3 | 297.14852 [M+H]+, 237.04, 251.65, 279.07 | 25.89 | [ |
| 21 | Tanshinone I | C18H12O3 | 277.08592 | 26.15 | * |
| 22 | Senkyunolides P | C24H30O4 | 383.22168 [M+H]+, 383.32, 355.25, 365.20 | 29.75 | [ |
| 23 | Tanshinone II A | C19H18O3 | 295.13287 [M+H]+, 249.13, 277.11 | 30.06 | [ |
* Compared with a standard. Other components were identified through comparison with m/z and mass fragmentation patterns reported in the literature
Fig. 4PCA of lipids in samples and QCs: a positive ion mode; b negative ion mode
Fig. 5PLSDA of lipids in the KOA rats: a, c positive ion mode; b, d negative ion mode
Fig. 6Heat map of identified differential lipids based on the positive (a) and negative (b) ion modes between the control group and the KOA group
Significantly changed metabolites in each group
| Name | FC (KOA/control) | P. adjusted (KOA/control) | FC (Sanse powder/KOA) | P. adjusted (Sanse powder/KOA) |
|---|---|---|---|---|
| (A) Positive ion mode | ||||
| DAG 38:5; DAG 18:1-20:4 | 0.24397 | 0.00688 | 2.85705 | 0.00820 |
| DAG 38:6; DAG 18:2-20:4 | 0.05126 | 0.00688 | 5.36171 | 0.01939 |
| DAG 38:7; DAG 18:2-20:5 | 0.26403 | 0.00688 | 2.18564 | 0.02927 |
| LPC 18:0(SN2) | 0.08403 | 0.00688 | 6.48339 | 0.00820 |
| LPC 20:3(SN1) | 0.04763 | 0.00688 | 35.57942 | 0.00820 |
| LPC 24:0(SN2) | 10.12183 | 0.00688 | 0.15465 | 0.00820 |
| PC 20:0e; PC 18:0e/2:0 | 0.01511 | 0.02103 | 84.63364 | 0.00820 |
| PC 34:4; PC 17:2-17:2 | 0.10140 | 0.00688 | 5.27038 | 0.01939 |
| PC 38:4; PC 18:0-20:4 | 0.20891 | 0.00688 | 1.54615 | 0.00820 |
| TAG 52:5; TAG 16:0-16:1-20:4 | 0.03330 | 0.02103 | 35.65847 | 0.01669 |
| TAG 54:4; TAG 16:0-18:0-20:4 | 0.04690 | 0.00688 | 13.83490 | 0.00820 |
| TAG 56:5; TAG 18:0-18:1-20:4 | 0.28945 | 0.02103 | 2.73175 | 0.04829 |
| TAG 58:11; TAG 16:0-20:5-22:6 | 0.46693 | 0.02103 | 2.37085 | 0.00820 |
| TAG 58:12; TAG 18:2-20:5-20:5 | 0.53100 | 0.01641 | 2.04412 | 0.01422 |
| TAG 58:3; TAG 18:1-18:2-22:0 | 0.62809 | 0.03199 | 1.52464 | 0.02927 |
| TAG 60:10; TAG 18:0-20:4-22:6 | 0.29493 | 0.00688 | 1.88914 | 0.01939 |
| TAG 60:11; TAG 18:1-20:4-22:6 | 0.66509 | 0.02103 | 1.53073 | 0.00820 |
| TAG 60:11; TAG 18:2-20:4-22:5 | 0.07639 | 0.00688 | 12.63757 | 0.00820 |
| TAG 60:4; TAG 18:1-20:3-22:0 | 0.56576 | 0.02103 | 1.64774 | 0.00820 |
| TAG 64:17; TAG 20:5-22:6-22:6 | 0.02183 | 0.03199 | 36.57651 | 0.00820 |
| (B) Negative ion mode | ||||
| FAHFA 40:4; FAHFA 18:1/22:3 | 0.13704 | 0.00869 | 2.15629 | 0.04779 |
| PE 40:4; PE 20:0-20:4 | 0.34231 | 0.00683 | 1.56335 | 0.04779 |
Fig. 7The effects of “Sanse powder” on lipid levels in KOA. PAF platelet activating factor, PLA2 phospholipase A2